A Modified Case Control Study to Identify Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate.
Phase of Trial: Phase II/III
Latest Information Update: 13 Jul 2016
At a glance
- Drugs Lapaquistat (Primary)
- Indications Hyperlipidaemia
- Focus Adverse reactions; Pharmacogenomic
- Sponsors Takeda
- 23 May 2012 Additional trial locations added as reported by ClinicalTrials.gov.
- 29 Jul 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
- 29 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.